Luspatercept
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
- Luspatercept
- Luspatercept: From Anemia in β-Thalassemia/MDS to Pyruvate Kinase Deficiency of Red Cells
Luspatercept: From Anemia in β-Thalassemia/MDS to Pyruvate Kinase Deficiency of Red Cells
One-Sentence Summary
Luspatercept is a biologic used internationally to treat anemia associated with transfusion-dependent β-thalassemia and myelodysplastic syndromes (MDS), both driven by ineffective erythropoiesis. The TxGNN model predicts it may also be relevant for Pyruvate Kinase Deficiency of Red Cells, a hereditary hemolytic anemia with a similar underlying pathophysiology. However, this prediction is currently supported by 0 clinical trials and 0 publications — it is a pure computational hypothesis (L5) that has not yet been tested.
Note on candidate selection: This Evidence Pack contains 10 TxGNN-predicted indications for luspatercept. The single highest-scoring prediction (monosomy X, score 95.99%) is explicitly flagged in the evidence pack’s own rationale as likely knowledge-graph noise with no plausible mechanistic link. Among the 10 candidates, only three (Pyruvate Kinase Deficiency, Thalassemia beta+ silent allele, Hb Bart’s hydrops fetalis) reach decision stage S1 (“Research Question”) rather than S0 (“Hold”). This report focuses on Pyruvate Kinase Deficiency of Red Cells as the most biologically coherent and clinically meaningful candidate; the full candidate landscape is summarized near the end of this report.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available from Taiwan regulatory data (drug not marketed in Taiwan). Per evidence-pack rationale text, internationally approved for anemia in transfusion-dependent β-thalassemia and MDS |
| Predicted New Indication | Pyruvate Kinase Deficiency of Red Cells |
| TxGNN Prediction Score | 93.84% (rank 43,686 of all drug-disease pairs) |
| Evidence Level | L5 — model prediction only, no clinical trials or literature |
| Taiwan Market Status | Not marketed (Not marketed) |
| Number of Authorizations | 0 |
| Recommended Decision | Hold (flagged internally as “Research Question”) |
Why is This Prediction Reasonable?
Detailed formal mechanism-of-action data is flagged as a data gap (DG002) in this evidence pack. However, the pack’s own rationale text describes luspatercept as an ActRIIB-Fc fusion protein (“ligand trap”) that binds TGF-β superfamily ligands (GDF11, activin B) and inhibits downstream Smad2/3 signaling, thereby promoting late-stage erythroid maturation. This mechanism is distinct from erythropoietin-stimulating agents, acting instead on the terminal differentiation step of red blood cell production.
Luspatercept’s established indications — β-thalassemia and MDS — share a common pathophysiological feature: ineffective erythropoiesis, where red blood cell precursors fail to mature properly, leading to chronic anemia despite adequate or excessive erythroid precursor numbers. Pyruvate kinase (PK) deficiency of red cells is a hereditary enzymopathy causing chronic hemolytic anemia with a compensatory but ineffective erythropoiesis response — mechanistically analogous to the underlying biology luspatercept already addresses in its approved indications.
Because luspatercept acts downstream, at the late erythroid maturation stage rather than on a disease-specific upstream defect, there is a plausible (though untested) rationale that it could partially normalize red cell output in PK deficiency as well. This is explicitly framed in the evidence pack as a hypothesis extrapolated from mechanistic analogy, not as evidence of proven efficacy — safety data on the use of luspatercept in a distinct hemolytic anemia population are entirely unavailable.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Taiwan Market Information
Luspatercept currently holds no marketing authorizations in Taiwan (market status: Not marketed, total licenses: 0). No product, dosage form, or approved indication text is available from the local regulatory dataset for this evidence pack.
Safety Considerations
Please refer to the SmPC for safety information.
Critical data gap: TFDA label warnings and contraindications (DG001) are marked as a Blocking data gap in this evidence pack — this must be resolved before any safety-stage (S1) evaluation can proceed. No drug-drug interaction data was found (query_status: not_found).
Other Predicted Indications in This Evidence Pack
For transparency, the full set of 10 TxGNN-predicted indications for luspatercept is summarized below, ranked by TxGNN score. Only three reach decision stage S1 (“Research Question”); the rest are held at S0 due to weak or absent mechanistic plausibility per the evidence pack’s own rationale.
| Rank | Disease | TxGNN Score | Decision Stage | Recommendation | Mechanistic Plausibility |
|---|---|---|---|---|---|
| 1 | Monosomy X (Turner syndrome) | 95.99% | S0 | Hold | Likely KG noise — no direct link |
| 2 | Hepatic infarction | 95.70% | S0 | Hold | No plausible pathway |
| 3 | Hepatic veno-occlusive disease | 94.91% | S0 | Hold | Speculative TGF-β/fibrosis link, unvalidated |
| 4 | Peliosis hepatis | 94.75% | S0 | Hold | No direct mechanistic link |
| 5 | Combined immunodeficiency syndrome | 94.28% | S0 | Hold | No plausible pathway |
| 6 | Pyruvate kinase deficiency of red cells | 93.84% | S1 | Research Question | Shared ineffective erythropoiesis biology |
| 7 | Thalassemia, beta+, silent allele | 93.32% | S1 | Research Question | Mechanistically overlaps with approved β-thalassemia indication |
| 8 | Familial apolipoprotein C-II deficiency | 93.05% | S0 | Hold | No known pathway overlap |
| 9 | Adenosine deaminase deficiency | 92.86% | S0 | Hold | No plausible pathway |
| 10 | Hb Bart’s hydrops fetalis | 92.75% | S1 | Research Question | Same thalassemia-family biology; fetal safety unknown |
Conclusion and Next Steps
Decision: Hold
Rationale: This prediction is supported only by mechanistic analogy (L5, model prediction only) with zero clinical trials and zero publications. Additionally, luspatercept is not currently marketed in Taiwan, and a Blocking safety data gap (TFDA warnings/contraindications) prevents any progression to a formal safety-stage evaluation.
To proceed, the following is needed:
- Resolve DG001 (Blocking): obtain TFDA/international label warnings and contraindications
- Resolve DG002 (High): confirm formal MOA documentation via DrugBank API
- Identify or commission preclinical/proof-of-concept data specific to PK deficiency of red cells
- Monitor ClinicalTrials.gov and PubMed for emerging evidence, as this candidate is currently a pure research question with no active studies
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.